



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 07-09-2010

News / Story reproduced with thanks:- **Financial Express**

Advinus may outlicence diabetes molecule soon

fe Bureau

Posted: Tuesday, Sep 07, 2010 at 2232 hrs IST

Updated: Tuesday, Sep 07, 2010 at 2232 hrs IST

Direct link to the News/Story:-

<http://www.financialexpress.com/news/Advinus-may-outlicence-diabetes-molecule-soon/678032/>

Hyderabad: Advinus Therapeutics, a research-based pharma company promoted by the Tata group, is in the final stage of its research and is planning for the next phase. The company is expected to outlicence its molecule for treating type II diabetes in the next six months.

The company would initiate talks with leading pharma companies along with the trial reports for the same. Incidentally, it is the first 'Made in India' molecule for treatment of diabetes.

According to R Gopalakrishnan, ED, Tata Sons, the molecule has completed its first stage. "We are hoping to licence the molecule in the next six months," he said. "The ramp up is expected to happen after six months after we get one or two successful molecules," he added. The molecule, GKM -001, is an activator of glucokinase; an enzyme that regulates glucose balance and insulin secretion in the body. GKM-001 is completely indigenously developed molecule and the initial clinical trials have shown excellent results for both safety and efficacy.

The company is the first of its kind in the country to offer end-to-end development services to the global pharma, agro and biotech industries